Edition:
United States

Benitec Biopharma Ltd (BNTC.OQ)

BNTC.OQ on NASDAQ Stock Exchange Capital Market

3.60USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$3.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,730
52-wk High
$5.48
52-wk Low
$1.85

Chart for

About

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​

* ‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​ Source text for Eikon: Further company coverage:

Jan 14 2018

BRIEF-Benitec Biopharma Posts Qtrly ‍Loss Of A$2.9 mln

* QTRLY ‍LOSS OF A$2.9 MILLION VERSUS PROFIT OF A$0.8 MILLION​ Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Benitec Biopharma provides update On Opmd Orphan Disease program

* BENITEC BIOPHARMA PROVIDES UPDATE ON OPMD ORPHAN DISEASE PROGRAM

Nov 27 2017

Earnings vs. Estimates